GCM
BMY.RT

Gables Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Gables Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,575
Closed -$1K – 386
2020
Q4 		$1K Hold
1,575
– – ﹤0.01% 355
2020
Q3 		$4K Hold
1,575
– – ﹤0.01% 341
2020
Q2 		$6K Hold
1,575
– – ﹤0.01% 316
2020
Q1 		$4K Buy
+1,575
New +$5.19K ﹤0.01% 358

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Gables Capital Management's BMY.RT Position: Q1 2021 in Review

Gables Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,575 shares — an estimated $1K sold.

Gables Capital Management first reported a position in BMY.RT in Q1 2020 and held it in 4 quarters. The position peaked at $6K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Gables Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Gables Capital Management sold 1,575 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Gables Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q1 2020 and held it in 4 quarters.
  • Gables Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $6K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Gables Capital Management's 13F filing for Q1 2021, filed 12 May 2021.